Sotac Pharmaceuticals Ltd Stock Price Today (NSE: SOTAC)
Fundamental Score
Sotac Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sotac Pharmaceuticals Ltd share price today is ₹94.90, up +10.35% on NSE/BSE as of 6 August 2026. Sotac Pharmaceuticals Ltd (SOTAC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹105.09 (Cr). The 52-week high for SOTAC share price is ₹139.65 and the 52-week low is ₹86.00. At a P/E ratio of 18.21x, SOTAC is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 10.29% and a debt-to-equity ratio of 0.64.
Sotac Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Sotac Pharmaceuticals Ltd share price chart: -12.43% return over the past month. 52-week high ₹139.65, 52-week low ₹86.00.
Sotac Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹86.00 | ₹94.90 | ₹86.00 | ₹91.95 | 3.60K (Cr) | |
| ₹90.40 | ₹90.40 | ₹90.40 | ₹90.40 | 1.20K (Cr) | |
| ₹95.10 | ₹95.10 | ₹95.10 | ₹95.10 | 2.40K (Cr) | |
| ₹105.00 | ₹105.00 | ₹105.00 | ₹105.00 | 49.20K (Cr) | |
| ₹104.00 | ₹105.00 | ₹104.00 | ₹105.00 | 2.40K (Cr) | |
| ₹111.00 | ₹111.00 | ₹111.00 | ₹111.00 | 1.20K (Cr) | |
| ₹111.00 | ₹111.00 | ₹111.00 | ₹111.00 | 1.20K (Cr) | |
| ₹111.30 | ₹111.30 | ₹111.30 | ₹111.30 | 1.20K (Cr) | |
| ₹111.30 | ₹111.30 | ₹111.30 | ₹111.30 | 3.60K (Cr) | |
| ₹106.00 | ₹106.00 | ₹106.00 | ₹106.00 | 2.40K (Cr) |
Sotac Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹105.00 | ₹105.00 | ₹86.00 | ₹91.95 | -12.43% | |
| ₹104.00 | ₹105.00 | ₹104.00 | ₹105.00 | +0.96% | |
| ₹106.00 | ₹111.30 | ₹106.00 | ₹111.00 | +4.72% | |
| ₹108.00 | ₹117.00 | ₹108.00 | ₹117.00 | +8.33% | |
| ₹115.00 | ₹115.00 | ₹115.00 | ₹115.00 | +0.00% | |
| ₹125.00 | ₹125.00 | ₹118.75 | ₹118.75 | -5.00% | |
| ₹117.05 | ₹118.50 | ₹100.00 | ₹118.30 | +1.07% | |
| ₹139.65 | ₹139.65 | ₹123.10 | ₹123.10 | -11.85% | |
| ₹129.00 | ₹131.25 | ₹122.55 | ₹125.00 | -3.10% | |
| ₹108.10 | ₹130.00 | ₹108.10 | ₹129.85 | +20.12% | |
| ₹137.55 | ₹137.55 | ₹108.10 | ₹108.10 | -21.41% | |
| ₹130.85 | ₹137.55 | ₹119.75 | ₹137.55 | +5.12% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Sotac is a microcap contract manufacturer riding the generic pharma wave, but liquidity risk and order concentration keep it on the watchlist.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Last notable news was on April 6, 2026, where Sotac Pharmaceuticals made further investments of million in its unit, Sotac Lifesciences, increasing its holding from 51.00% to 51.26%.
CORE STORY (THE REAL GAME)
Sotac is a contract manufacturer playing the generic pharma upswing in India. Not a branded player, but a B2B supplier riding the wave of increased pharma exports and domestic demand.
- Order wins from Intas and Cadila demonstrate manufacturing capabilities
- Industry tailwinds from increased pharma exports
- Backward integration into APIs improves supply chain
- Significant new order wins
- Successful API backward integration
- Improved profitability and cash flow
- Microcap/SME = liquidity risk
- Reliance on contract manufacturing = order cancellation risk
- Concentrated revenue = customer concentration risk
FII increased by 1.02%. DII decreased by 0.68%.
Indian pharma sector projected to reach $130 billion by 2030, a tailwind for contract manufacturers.
Received a purchase order from Intas Pharmaceuticals Limited for ₹48.76 lakh in Feb 2026. Received a purchase order from Cadila Pharmaceuticals Limited for ₹1.39 Cr in Feb 2026.
Free Cash Flow 5Y: ₹None Cr - Profitability not converting to cash.
Sotac's near-term performance hinges on securing new manufacturing contracts. Successful backward integration into APIs is crucial for long-term margin expansion.
Primary Thesis Risk
Reliance on contract manufacturing makes Sotac vulnerable to order cancellations and pricing pressure.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sotac Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sotac Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SOTAC across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 18.21 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (27.41%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (15.70% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (20.18% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (34.70% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (72.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Profit Decline Concern (-45.66%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Sotac Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sotac Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
51.7/100 | ₹94.90₹95 | ₹105.09₹105.09 | 18.21Average 18.2 Average | 10.29%Average 10.29% Average | 12.55%Average 12.55% Average | 0.64Good 0.6 Good | 34.70%Excellent 34.70% Excellent | 15.70%Excellent 15.70% Excellent | 0.11% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Sotac Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for SOTAC — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹3.90 | ₹109.30 | 28x |
| FY 2023 | ₹2.61 | ₹118.00 | 45.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sotac Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by SOTAC — dividend yield 0.11%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹0.46 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Sotac Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for SOTAC — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
27.41%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-45.66%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.70%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
34.70%
Compounded annual net profit growth over 5 years
Sotac Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SOTAC — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Sotac Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Sotac Pharmaceuticals Ltd (SOTAC) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Sotac Pharmaceuticals Ltd
About SOTAC (Sotac Pharmaceuticals Ltd)
Sotac Pharmaceuticals Ltd (SOTAC) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a... current market capitalisation of ₹105.09 (Cr). Sotac Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 10.29% and a ROCE of 12.55%. The debt-to-equity ratio stands at 0.64, reflecting the company's capital structure. Investors tracking SOTAC share price can monitor key metrics including P/E ratio, promoter holding of 72.85%, and quarterly earnings growth.
Company Details
SOTAC Share Price: Frequently Asked Questions
What is the current share price of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd (SOTAC) trades at ₹94.90 on NSE. Market cap ₹105.09 (Cr). Educational data only.
What is the P/E ratio of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd has a P/E of 18.21x vs industry average 34.89x.
What is the Bull Run score for Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd has a Bull Run score of 51.7/100 based on 25+ financial parameters.
Does Sotac Pharmaceuticals Ltd pay dividends?
Sotac Pharmaceuticals Ltd has a dividend yield of 0.11%. Past dividends don't guarantee future payments.
What is the ROE of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd has ROE of 10.29%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd has debt-to-equity of 0.64.
Is Sotac Pharmaceuticals Ltd a good investment?
Bull Run gives Sotac Pharmaceuticals Ltd a score of 51.7/100. This is not investment advice — consult a SEBI-registered advisor.